[Remdesivir, the antiviral hope against SARS-CoV-2].
Identifieur interne : 000099 ( PubMed/Corpus ); précédent : 000098; suivant : 000100[Remdesivir, the antiviral hope against SARS-CoV-2].
Auteurs : J. ReinaSource :
- Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia [ 1988-9518 ] ; 2020.
Abstract
On December 31, 2019 a pneumonia outbreak caused by a new coronavirus (SARS-CoV-2) was detected in the city of Wuhan (China). Due to the high capacity of diffusion and human infection it has become a new zoonotic pandemic. The absence of a vaccine has determined the search for antiviral drugs with the capacity to inhibit the replication of the new virus. Among them, remdesivir, an analogue of adenosine, is what seems to have a more promising future. This drug has shown in vitro and in animals a high capacity to block infection and viral replication with attainable concentrations in human plasma. Although all studies have been carried out with SARS-CoV and MERS-CoV, it seems that by virological and functional analogy, remdesivir is one of the few antiviral drugs with proven efficacy. However, studies and clinical trials in humans are required to know the result of their application in them.
DOI: 10.37201/req/098.2020
PubMed: 32239125
Links to Exploration step
pubmed:32239125Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Remdesivir, the antiviral hope against SARS-CoV-2].</title>
<author><name sortKey="Reina, J" sort="Reina, J" uniqKey="Reina J" first="J" last="Reina">J. Reina</name>
<affiliation><nlm:affiliation>Jordi Reina, Unidad de Virología, Servicio de Microbiología, Hospital Universitario Son Espases, Facultad de Medicina (UIB). Carretera Valldemossa 79, 07120 Palma de Mallorca. Spain. jorge.reina@ssib.es.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32239125</idno>
<idno type="pmid">32239125</idno>
<idno type="doi">10.37201/req/098.2020</idno>
<idno type="wicri:Area/PubMed/Corpus">000099</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000099</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Remdesivir, the antiviral hope against SARS-CoV-2].</title>
<author><name sortKey="Reina, J" sort="Reina, J" uniqKey="Reina J" first="J" last="Reina">J. Reina</name>
<affiliation><nlm:affiliation>Jordi Reina, Unidad de Virología, Servicio de Microbiología, Hospital Universitario Son Espases, Facultad de Medicina (UIB). Carretera Valldemossa 79, 07120 Palma de Mallorca. Spain. jorge.reina@ssib.es.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia</title>
<idno type="eISSN">1988-9518</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">On December 31, 2019 a pneumonia outbreak caused by a new coronavirus (SARS-CoV-2) was detected in the city of Wuhan (China). Due to the high capacity of diffusion and human infection it has become a new zoonotic pandemic. The absence of a vaccine has determined the search for antiviral drugs with the capacity to inhibit the replication of the new virus. Among them, remdesivir, an analogue of adenosine, is what seems to have a more promising future. This drug has shown in vitro and in animals a high capacity to block infection and viral replication with attainable concentrations in human plasma. Although all studies have been carried out with SARS-CoV and MERS-CoV, it seems that by virological and functional analogy, remdesivir is one of the few antiviral drugs with proven efficacy. However, studies and clinical trials in humans are required to know the result of their application in them.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32239125</PMID>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>04</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1988-9518</ISSN>
<JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year>
<Month>04</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia</Title>
<ISOAbbreviation>Rev Esp Quimioter</ISOAbbreviation>
</Journal>
<ArticleTitle>[Remdesivir, the antiviral hope against SARS-CoV-2].</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">reina01apr2020</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.37201/req/028.2020</ELocationID>
<Abstract><AbstractText>On December 31, 2019 a pneumonia outbreak caused by a new coronavirus (SARS-CoV-2) was detected in the city of Wuhan (China). Due to the high capacity of diffusion and human infection it has become a new zoonotic pandemic. The absence of a vaccine has determined the search for antiviral drugs with the capacity to inhibit the replication of the new virus. Among them, remdesivir, an analogue of adenosine, is what seems to have a more promising future. This drug has shown in vitro and in animals a high capacity to block infection and viral replication with attainable concentrations in human plasma. Although all studies have been carried out with SARS-CoV and MERS-CoV, it seems that by virological and functional analogy, remdesivir is one of the few antiviral drugs with proven efficacy. However, studies and clinical trials in humans are required to know the result of their application in them.</AbstractText>
<CopyrightInformation>©The Author 2020. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reina</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Jordi Reina, Unidad de Virología, Servicio de Microbiología, Hospital Universitario Son Espases, Facultad de Medicina (UIB). Carretera Valldemossa 79, 07120 Palma de Mallorca. Spain. jorge.reina@ssib.es.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>spa</Language>
<PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<VernacularTitle>Remdesivir, la esperanza antiviral frente al SARS-CoV-2.</VernacularTitle>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Spain</Country>
<MedlineTA>Rev Esp Quimioter</MedlineTA>
<NlmUniqueID>9108821</NlmUniqueID>
<ISSNLinking>0214-3429</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword>
<Keyword MajorTopicYN="Y">remdesivir</Keyword>
<Keyword MajorTopicYN="Y">treatment</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>4</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32239125</ArticleId>
<ArticleId IdType="doi">10.37201/req/098.2020</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000099 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000099 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:32239125 |texte= [Remdesivir, the antiviral hope against SARS-CoV-2]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:32239125" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a MersV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |